EA Policies for Single Patient
Since no expanded access program (EAP) has been initiated for QLS1304 for the treatment of advanced solid tumor patients in the US, according to company policy, Shanghai Qilu Pharmaceutical Research and Development Center encourages all potentially eligible patients to be considered for enrolment in the clinical study.
For more information, please refer to our company website (https://en.qilu-pharma.com/news_details/6.html).